We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

U.S. Patent Granted for 4SC’s Oral HDAC Inhibitor Resminostat (4SC-201)

News   Dec 08, 2010

 
U.S. Patent Granted for 4SC’s Oral HDAC Inhibitor Resminostat (4SC-201)
 
 
Advertisement
 

RELATED ARTICLES

UK Researchers Set To Explore Human Challenge Studies for COVID-19 Vaccine Development

News

Researchers are set to explore a human challenge study with the virus that causes COVID-19, the first such study anywhere in the world.

READ MORE

Glutathione Precursor Improves Conditions Associated With Premature Aging in HIV Patients

News

An open-label clinical trial found that a glutathione precursor, GlyNAC, reverses premature aging in people with HIV.

READ MORE

NIH Study Designed To Identify Promising COVID-19 Treatments for Larger Clinical Trials

News

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today launched a study designed to determine whether certain approved therapeutics or investigational drugs in late clinical development show promise against COVID-19 and warrant advancement into larger clinical trials.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE